A Study to Assess the Engagement and Usefulness of Care4Today Digital Platform for Disease Management in Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD) Population
- Conditions
- Coronary Artery Disease (CAD)Peripheral Artery Disease (PAD)
- Interventions
- Device: Care4Today® Connect CAD-PAD Mobile Application
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 277
- Registration Number
- NCT06052319
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸HCA Florida Memorial Hospital, Jacksonville, Florida, United States
🇺🇸University of Florida Health Jacksonville, Jacksonville, Florida, United States
A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 86
- Registration Number
- NCT05347485
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Washington University School Of Medicine, Saint Louis, Missouri, United States
🇺🇸City of Hope, Duarte, California, United States
Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Registration Number
- NCT05346835
A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain
- Conditions
- HIV-1
- Interventions
- Drug: D/C/F/TAF FDCDrug: TAF/FTC FDCDrug: INI Based Regimen
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 103
- Registration Number
- NCT04442737
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸The Office of Franco Felizarta, MD, Bakersfield, California, United States
🇺🇸AIDS Health Foundation-Westside HCC, Beverly Hills, California, United States
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
- Conditions
- Crohn DiseaseColitis, Ulcerative
- Interventions
- Drug: Other Biologic Therapies
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 1056
- Registration Number
- NCT04372108
- Locations
- 🇺🇸
NMCP, Portsmouth, Virginia, United States
A Study to Investigate if Early Atrial Fibrillation (AF) Diagnosis Reduces Risk of Events Like Stroke in the Real-World
- Conditions
- Atrial Fibrillation
- Interventions
- Device: Heart healthy Engagement Program with the Apple Watch Series 5 or laterDevice: Anti-Coagulation Adherence Module with the Apple Watch Series 5 or later
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 34244
- Registration Number
- NCT04276441
- Locations
- 🇺🇸
Evidation Health, San Mateo, California, United States
Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options
- Conditions
- Advanced Cancers and FGFR Genetic Alterations
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Registration Number
- NCT03825484
Sustainable Early Episode Clinic Study (SEEC)
- Conditions
- Schizoaffective DisorderSchizophrenia
- Interventions
- Behavioral: Sustainable Early Episode Clinic Model of Care
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 50
- Registration Number
- NCT03571685
- Locations
- 🇺🇸
Sharp Outpatient Behavioral Health Clinic, San Diego, California, United States
Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year
- Conditions
- Crohn Disease
- Interventions
- Biological: Ustekinumab (6 mg/kg)Biological: Adalimumab (40 mg)Biological: Ustekinumab (90 mg)
- First Posted Date
- 2018-03-13
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 386
- Registration Number
- NCT03464136
- Locations
- 🇺🇸
Alabama Medical Group, Mobile, Alabama, United States
🇺🇸Precision Research Institute, San Diego, California, United States
🇺🇸Peak Gastroenterology Associates, Colorado Springs, Colorado, United States
A Study to Quantify Use of Anticoagulation to Improve Management of Atrial Fibrillation
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2019-12-26
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 2000
- Registration Number
- NCT03382613
- Locations
- 🇺🇸
Banner Thunderbird, Glendale, Arizona, United States
🇺🇸Banner Desert Medical Center, Mesa, Arizona, United States
🇺🇸Banner Baywood Medical Center, Mesa, Arizona, United States